Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299234 · ClinicalTrials.gov registry record · Phase 4
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
A Phase 4 study, sponsored by Monarch Medical Research.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT00299234: Clinical Trial Phase 4 study, sponsored by Monarch Medical Research.
NCT00299234 is a Phase 4 study that was terminated before completion, run by Monarch Medical Research. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00299234, a Phase 4 study, was terminated before completion, sponsored by Monarch Medical Research.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is a double-blind, placebo-controlled, parallel group trial of atomoxetine (1.8 mg/kg) for the management of chemotherapy-related acquired attentional disorders in children who have survived Acute Lymphocytic Leukemia. Atomoxetine will produce a favorable impact on ADHD symptoms in children with chemo-related acquired attentional disorders.
Interventions
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Why NCT00299234 stopped before completion
NCT00299234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00299234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00299234 about?
NCT00299234 is a clinical study titled "Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL". This study is a double-blind, placebo-controlled, parallel group trial of atomoxetine (1.8 mg/kg) for the management of chemotherapy-related acquired attentional disorders in children who have survived Acute Lymphocytic Leukemia. Atomoxetine will produce a favorable impact on ADHD symptoms in childr...
What is the current status of trial NCT00299234?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2006-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00299234?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00299234?
This trial is sponsored by Monarch Medical Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00299234's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia